Roche Raises Outlook Despite US Biosimilars, Sees Spark Buy By Year-End

Roche presented a strong first-half performance and raised its outlook again for the full year as sales continued to be driven by its portfolio of new medicines. It said its delayed takeover of Spark Therapeutics should happen by year-end.